<DOC>
	<DOC>NCT00819013</DOC>
	<brief_summary>This multi-center study will be conducted in the United States with up to 80 healthy adult subjects. Subjects will be scheduled to receive a total of two (2) injections with 1 injection each administered. Subjects will be randomized according to a randomization scheme.</brief_summary>
	<brief_title>Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults</brief_title>
	<detailed_description>All subjects will be followed up for 60 days post-randomization and through the influenza season. Following the influenza season, a subset of the subjects will receive a booster vaccine at the 12 month time point. The subjects will further be assessed at 2 days, 7 days, 15 days, 30 days and 6 months following the booster vaccination.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult males or females 18 40 years of age in good general health Known allergies or severe reactions to any of the vaccine components including those to adjuvants History of severe allergic reactions, including angioedema; History of asthma or recurrent wheezing; (current or within past 2 years); History of neurological symptoms or signs following administration of any vaccine;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>